Enveric Biosciences Q3 2026 Results: Net Loss of $2.55M, Loss Widens
Enveric Biosciences reported a net loss of $7.21 million for the nine months ended September 30, 2026, compared to $6.58 million in the prior year period, driven by increased research and development costs. The company strengthened its cash position to $5.61 million through various financing activities, including private placements and warrant exercises, resulting in a total shareholders' equity of $5.73 million.
- Key figure
- Net loss $2.55M